On November 2, 2011 Fresenius Medical Care AG & Co. KGaA (the “Company”) issued an Investor News announcing its third quarter results for the period ending September 30, 2011. A copy of the Investor News is furnished as Exhibit 99.1.
The attached Investor News contains non-GAAP financial measures. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles. To supplement our third quarter 2011 consolidated financial results presented in accordance with Generally Accepted Accounting Principles in the United States, or GAAP, we have used non-GAAP financial measure of (a) EBITDA, or operating income excluding interest, taxes, depreciation and amortization, and (b) free cash flow. These non-GAAP measures are provided to enhance the user’s overall understanding of our current financial performance and our prospects for the future. In addition, because we have historically reported certain non-GAAP financial measures in our financial results, we believe the inclusion of these non-GAAP financial measures provides consistency and comparability in our financial reporting to prior periods for which these non-GAAP financial measures were previously reported. These non-GAAP financial measures should not be used as a substitute for or be considered superior to GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures are included in the attached Investor News in a separate statement setting forth the reconciliation and in the Cash Flow Statement.
The Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Fresenius Medical Care AG & Co. KGaA, | |||
a partnership limited by shares, represented by: | |||
fresenius medical care management ag, its | |||
general partner | |||
By:
|
/s/ Dr. Ben J. Lipps | ||
Name:
|
Dr. Ben J. Lipps
|
||
Title:
|
Chief Executive Officer and
Chairman of the Management Board of the General Partner |
||
By:
|
/s/ Michael Brosnan | ||
Name:
|
Michael Brosnan
|
||
Title:
|
Chief Financial Officer and
Member of the Management Board of the General Partner |
![]() |
||
Contact:
|
Fresenius Medical Care AG & Co. KGaA
|
|
Oliver Maier
|
Else-Kröner-Str.1
|
|
Phone:
|
+ 49 6172 609 2601
|
61352 Bad Homburg
|
Fax:
|
+ 49 6172 609 2301
|
Germany
|
www.fmc-ag.com
|
||
North America:
|
||
Terry L. Morris
|
||
Phone:
|
+ 1 800 948 2538
|
|
Fax:
|
+ 1 615 345 5605
|
|
E-mail:
|
ir@fmc-ag.com
|
November 2, 2011
|
Net revenue
|
$3,242 million
|
+6 | % | |||
Operating income (EBIT)
|
$534 million
|
+8 | % | |||
Net income attributable to
Fresenius Medical Care AG & Co. KGaA
|
$279 million
|
+13 | % | |||
Earnings per share
|
$0.92 | +12 | % |
Net revenue
|
$9,473 million
|
+7 | % | |||
Operating income (EBIT)
|
$1,488 million
|
+7 | % | |||
Net income attributable to
Fresenius Medical Care AG & Co. KGaA
|
$761 million
|
+8 | % | |||
Earnings per share
|
$2.51 | +7 | % |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
2 of 18
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
3 of 18
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
4 of 18
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
5 of 18
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
6 of 18
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
7 of 18
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
8 of 18
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
9 of 18
|
Fresenius Medical Care
|
Three months ended
|
Nine months ended
|
||||||||||||||||||||||
Statement of Earnings
|
September 30,
|
September 30,
|
||||||||||||||||||||||
(in $ thousands, except share data)
|
2011
|
2010
|
Change
|
2011
|
2010
|
Change
|
||||||||||||||||||
(unaudited)
|
||||||||||||||||||||||||
Net revenue
|
||||||||||||||||||||||||
Dialysis Care
|
2,425,092 | 2,321,175 | 4.5 | % | 7,071,971 | 6,716,280 | 5.3 | % | ||||||||||||||||
Dialysis Products
|
816,999 | 736,930 | 10.9 | % | 2,400,560 | 2,170,153 | 10.6 | % | ||||||||||||||||
Total net revenue
|
3,242,091 | 3,058,105 | 6.0 | % | 9,472,531 | 8,886,433 | 6.6 | % | ||||||||||||||||
Costs of revenue
|
2,088,252 | 2,003,627 | 4.2 | % | 6,161,666 | 5,856,055 | 5.2 | % | ||||||||||||||||
Gross profit
|
1,153,839 | 1,054,478 | 9.4 | % | 3,310,865 | 3,030,378 | 9.3 | % | ||||||||||||||||
Selling, general and administrative
|
598,433 | 540,291 | 10.8 | % | 1,764,361 | 1,583,612 | 11.4 | % | ||||||||||||||||
Research and development
|
27,612 | 22,794 | 21.1 | % | 80,544 | 67,256 | 19.8 | % | ||||||||||||||||
Income from equity method investees
|
(5,940 | ) | (1,857 | ) | 219.7 | % | (22,402 | ) | (5,484 | ) | 308.5 | % | ||||||||||||
Operating income (EBIT)
|
533,734 | 493,250 | 8.2 | % | 1,488,362 | 1,384,994 | 7.5 | % | ||||||||||||||||
Interest income
|
(16,882 | ) | (4,719 | ) | 257.7 | % | (42,882 | ) | (18,802 | ) | 128.1 | % | ||||||||||||
Interest expense
|
84,955 | 75,086 | 13.1 | % | 257,124 | 224,818 | 14.4 | % | ||||||||||||||||
Interest expense, net
|
68,073 | 70,367 | (3.3 | )% | 214,242 | 206,016 | 4.0 | % | ||||||||||||||||
Income before taxes
|
465,661 | 422,883 | 10.1 | % | 1,274,120 | 1,178,978 | 8.1 | % | ||||||||||||||||
Income tax expense
|
162,797 | 152,904 | 6.5 | % | 436,057 | 409,507 | 6.5 | % | ||||||||||||||||
Net income
|
302,864 | 269,979 | 12.2 | % | 838,063 | 769,471 | 8.9 | % | ||||||||||||||||
Less: Net income attributable to noncontrolling interests
|
23,609 | 22,191 | 6.4 | % | 77,346 | 62,298 | 24.2 | % | ||||||||||||||||
Net income attributable to FMC AG & Co. KGaA
|
279,255 | 247,788 | 12.7 | % | 760,717 | 707,173 | 7.6 | % | ||||||||||||||||
Operating income (EBIT)
|
533,734 | 493,250 | 8.2 | % | 1,488,362 | 1,384,994 | 7.5 | % | ||||||||||||||||
Depreciation and amortization
|
141,422 | 123,959 | 14.1 | % | 413,695 | 369,324 | 12.0 | % | ||||||||||||||||
EBITDA
|
675,156 | 617,209 | 9.4 | % | 1,902,057 | 1,754,318 | 8.4 | % | ||||||||||||||||
Total bad debt expenses
|
64,982 | 49,340 | 175,102 | 165,037 | ||||||||||||||||||||
Earnings per ordinary share
|
$ | 0.92 | $ | 0.82 | 11.9 | % | $ | 2.51 | $ | 2.35 | 6.7 | % | ||||||||||||
Earnings per ordinary ADS
|
$ | 0.92 | $ | 0.82 | 11.9 | % | $ | 2.51 | $ | 2.35 | 6.7 | % | ||||||||||||
Weighted average number of shares
|
||||||||||||||||||||||||
Ordinary shares
|
299,280,448 | 297,244,371 | 298,714,674 | 296,370,673 | ||||||||||||||||||||
Preference shares
|
3,964,914 | 3,914,044 | 3,960,315 | 3,901,126 | ||||||||||||||||||||
In percent of revenue
|
||||||||||||||||||||||||
Costs of revenue
|
64.4 | % | 65.5 | % | 65.0 | % | 65.9 | % | ||||||||||||||||
Gross profit
|
35.6 | % | 34.5 | % | 35.0 | % | 34.1 | % | ||||||||||||||||
Selling, general and administrative
|
18.5 | % | 17.7 | % | 18.6 | % | 17.8 | % | ||||||||||||||||
Research and development
|
0.9 | % | 0.7 | % | 0.9 | % | 0.8 | % | ||||||||||||||||
Income from equity method investees
|
(0.2 | )% | (0.1 | )% | (0.2 | )% | (0.1 | )% | ||||||||||||||||
Operating income (EBIT)
|
16.5 | % | 16.1 | % | 15.7 | % | 15.6 | % | ||||||||||||||||
Interest expense, net
|
2.1 | % | 2.3 | % | 2.3 | % | 2.3 | % | ||||||||||||||||
Income before taxes
|
14.4 | % | 13.8 | % | 13.5 | % | 13.3 | % | ||||||||||||||||
Income tax expense
|
5.0 | % | 5.0 | % | 4.6 | % | 4.6 | % | ||||||||||||||||
Net income attributable to Noncontrolling interests
|
0.7 | % | 0.7 | % | 0.8 | % | 0.7 | % | ||||||||||||||||
Net income attributable to FMC AG & Co. KGaA
|
8.6 | % | 8.1 | % | 8.0 | % | 8.0 | % | ||||||||||||||||
EBITDA
|
20.8 | % | 20.2 | % | 20.1 | % | 19.7 | % |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
10 of 18
|
Fresenius Medical Care
|
Three months ended
|
Nine months ended
|
||||||||||||||||||||||
Segment and Other Information
|
September 30,
|
September 30,
|
||||||||||||||||||||||
(in $ million)
|
2011
|
2010
|
Change
|
2011
|
2010
|
Change
|
||||||||||||||||||
(unaudited)
|
||||||||||||||||||||||||
Net revenue
|
||||||||||||||||||||||||
North America
|
2,050 | 2,071 | (1.0 | )% | 6,055 | 6,058 | (0.1 | )% | ||||||||||||||||
International
|
1,187 | 987 | 20.4 | % | 3,405 | 2,828 | 20.4 | % | ||||||||||||||||
Corporate
|
5 | — | — | 13 | — | — | ||||||||||||||||||
Total net revenue
|
3,242 | 3,058 | 6.0 | % | 9,473 | 8,886 | 6.6 | % | ||||||||||||||||
Operating income (EBIT)
|
||||||||||||||||||||||||
North America
|
375 | 374 | 0.2 | % | 1,035 | 1,014 | 2.1 | % | ||||||||||||||||
International
|
205 | 156 | 31.2 | % | 579 | 480 | 20.6 | % | ||||||||||||||||
Corporate
|
(46 | ) | (37 | ) | 23.9 | % | (126 | ) | (109 | ) | 15.2 | % | ||||||||||||
Total operating income (EBIT)
|
534 | 493 | 8.2 | % | 1,488 | 1,385 | 7.5 | % | ||||||||||||||||
Operating income in percentage of revenue
|
||||||||||||||||||||||||
North America
|
18.3 | % | 18.1 | % | 17.1 | % | 16.7 | % | ||||||||||||||||
International
|
17.3 | % | 15.8 | % | 17.0 | % | 17.0 | % | ||||||||||||||||
Total
|
16.5 | % | 16.1 | % | 15.7 | % | 15.6 | % | ||||||||||||||||
Employees
|
||||||||||||||||||||||||
Full-time equivalents
|
77,825 | 72,812 |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
11 of 18
|
Fresenius Medical Care
|
||||||||||||||||
Reconciliation of non US-GAAP
|
||||||||||||||||
financial measures to the most directly
|
Three Months Ended
|
Nine months ended
|
||||||||||||||
comparable US-GAAP financial measures
|
September 30,
|
September 30,
|
||||||||||||||
(in $ million)
|
2011
|
2010
|
2011
|
2010
|
||||||||||||
(unaudited)
|
||||||||||||||||
Segment information North America
|
||||||||||||||||
Net revenue
|
2,050 | 2,071 | ||||||||||||||
Costs of revenue and research and development
|
1,307 | 1,352 | ||||||||||||||
Selling, general and administrative
|
374 | 347 | ||||||||||||||
Income from equity method investees
|
(6 | ) | (2 | ) | ||||||||||||
Costs of revenue and operating expenses
|
1,675 | 1,697 | ||||||||||||||
Operating income (EBIT)
|
375 | 374 | ||||||||||||||
In percent of revenue
|
18.3 | % | 18.1 | % | ||||||||||||
Dialysis Products revenue incl. and excl. internal sales
|
||||||||||||||||
North America
|
||||||||||||||||
Dialysis products revenue incl. internal sales
|
401 | 390 | ||||||||||||||
less internal sales
|
(197 | ) | (182 | ) | ||||||||||||
Dialysis products external sales
|
204 | 208 | ||||||||||||||
International
|
||||||||||||||||
Dialysis products revenue incl. internal sales
|
723 | 616 | ||||||||||||||
less internal sales
|
(115 | ) | (87 | ) | ||||||||||||
Dialysis products external sales
|
608 | 529 | ||||||||||||||
|
||||||||||||||||
Reconciliation of cash flow from operating activities to EBITDA 1)
|
||||||||||||||||
Total EBITDA
|
1,902 | 1,754 | ||||||||||||||
Interest expense, net
|
(214 | ) | (206 | ) | ||||||||||||
Income tax expense
|
(436 | ) | (410 | ) | ||||||||||||
Change in working capital and other non-cash items
|
(302 | ) | (111 | ) | ||||||||||||
Net cash provided by operating activities
|
950 | 1,027 | ||||||||||||||
Annualized EBITDA
|
||||||||||||||||
Operating income (EBIT) last twelve months
|
2,027 | 1,876 | ||||||||||||||
Depreciation and amortization last twelve months
|
548 | 492 | ||||||||||||||
Non-cash charges
|
53 | 48 | ||||||||||||||
Annualized EBITDA
|
2,628 | 2,416 |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
12 of 18
|
Fresenius Medical Care
|
September 30,
|
December 31,
|
||||||
Balance Sheet
|
(unaudited)
|
(audited)
|
||||||
(in $ million)
|
2011
|
2010
|
||||||
Assets
|
||||||||
Current assets
|
5,588 | 5,153 | ||||||
Intangible assets
|
9,485 | 8,833 | ||||||
Other non-current assets
|
3,552 | 3,109 | ||||||
Total assets
|
18,625 | 17,095 | ||||||
Liabilities and equity
|
||||||||
Current liabilities
|
3,692 | 3,790 | ||||||
Long-term liabilities
|
6,718 | 5,501 | ||||||
Noncontrolling interest subject to put provisions
|
313 | 280 | ||||||
Total equity
|
7,902 | 7,524 | ||||||
Total liabilities and equity
|
18,625 | 17,095 | ||||||
Equity/assets ratio:
|
42 | % | 44 | % | ||||
Debt
|
||||||||
Short-term borrowings
|
161 | 671 | ||||||
Short-term borrowings from related parties
|
89 | 10 | ||||||
Current portion of long-term debt and capital lease obligations
|
974 | 264 | ||||||
Trust Preferred Securities
|
— | 625 | ||||||
Long-term debt and capital lease obligations, less current portion
|
5,487 | 4,310 | ||||||
Total debt
|
6,711 | 5,880 |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
13 of 18
|
Fresenius Medical Care
|
||||||||
Cash Flow Statement
|
||||||||
Nine Months Ended September 30,
|
2011
|
2010
|
||||||
(in $ million)
|
||||||||
(unaudited)
|
||||||||
Operating activities
|
||||||||
Net income
|
838 | 769 | ||||||
Depreciation / amortization
|
414 | 369 | ||||||
Change in working capital and other non cash items
|
(302 | ) | (111 | ) | ||||
Cash Flow from operating activities
|
950 | 1,027 | ||||||
Investing activities
|
||||||||
Purchases of property, plant and equipment
|
(397 | ) | (350 | ) | ||||
Proceeds from sale of property, plant and equipment
|
17 | 11 | ||||||
Capital expenditures, net
|
(380 | ) | (339 | ) | ||||
Free Cash Flow
|
570 | 688 | ||||||
Acquisitions, net of cash acquired and net purchases of intangible assets
|
(1,171 | ) | (247 | ) | ||||
Proceeds from divestitures
|
— | 8 | ||||||
Acquisitions, net of divestitures
|
(1,171 | ) | (239 | ) | ||||
Free Cash Flow after acquisitions, net of divestitures
|
(601 | ) | 449 | |||||
Investments, net of repayments
|
— | (131 | ) | |||||
Free Cash Flow after investing activities
|
(601 | ) | 318 | |||||
Financing activities
|
||||||||
Change in accounts receivable securitization program
|
(510 | ) | 281 | |||||
Change in intercompany debt
|
82 | — | ||||||
Change in other debt
|
1,815 | (125 | ) | |||||
Proceeds from exercise of stock options
|
69 | 93 | ||||||
Redemption of Trust Preffered Securities
|
(654 | ) | — | |||||
Distributions to noncontrolling interest
|
(95 | ) | (87 | ) | ||||
Contributions from noncontrolling interest
|
18 | 19 | ||||||
Dividends paid
|
(281 | ) | (232 | ) | ||||
Cash Flow from financing activities
|
444 | (51 | ) | |||||
Effects of exchange rates on cash
|
30 | 4 | ||||||
Net increase (decrease) in cash
|
(127 | ) | 271 | |||||
Cash at beginning of period
|
523 | 301 | ||||||
Cash at end of period
|
396 | 572 |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
14 of 18
|
Fresenius Medical Care
|
||||||||||||||||
Quarterly Performance Scorecard - Revenue
|
||||||||||||||||
Three months ended September 30,
|
2011
|
cc
|
2010
|
cc
|
||||||||||||
(in $ thousands, except per-treatment revenue)
|
||||||||||||||||
unaudited
|
||||||||||||||||
North America
|
||||||||||||||||
Net revenue
|
2,049,798 | 2,071,457 | ||||||||||||||
Growth year-over-year
|
(1.0 | )% | 6.3 | % | ||||||||||||
Dialysis care
|
1,845,691 | 1,863,088 | ||||||||||||||
Growth year-over-year
|
(0.9 | )% | 7.1 | % | ||||||||||||
U.S. per treatment
|
345 | 359 | ||||||||||||||
Per treatment
|
337 | 351 | ||||||||||||||
Sequential growth
|
(1.0 | )% | 0.8 | % | ||||||||||||
Growth year-over-year
|
(4.2 | )% | 2.8 | % | ||||||||||||
Dialysis products
|
||||||||||||||||
incl. internal sales
|
401,486 | 390,336 | ||||||||||||||
Growth year-over-year
|
2.9 | % | 3.9 | % | ||||||||||||
External sales
|
204,107 | 208,369 | ||||||||||||||
Growth year-over-year
|
(2.0 | )% | (0.5 | )% | ||||||||||||
International
|
||||||||||||||||
Net revenue
|
1,187,436 | 986,569 | ||||||||||||||
Growth year-over-year
|
20.4 | % | 12.9 | % | 5.1 | % | 9.4 | % | ||||||||
Dialysis care
|
579,401 | 458,087 | ||||||||||||||
Growth year-over-year
|
26.5 | % | 19.8 | % | 12.7 | % | 16.7 | % | ||||||||
Per treatment
|
170 | 161 | 160 | 165 | ||||||||||||
Sequential growth
|
(4.3 | )% | 0.5 | % | ||||||||||||
Growth year-over-year
|
6.5 | % | 0.8 | % | (4.6 | )% | (1.2 | )% | ||||||||
Dialysis products
|
||||||||||||||||
incl. internal sales
|
722,894 | 616,166 | ||||||||||||||
Growth year-over-year
|
17.3 | % | 9.3 | % | 0.4 | % | 5.1 | % | ||||||||
External sales
|
608,035 | 528,482 | ||||||||||||||
Growth year-over-year
|
15.1 | % | 6.9 | % | (0.8 | )% | 3.8 | % | ||||||||
cc = at constant currency1
|
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
15 of 18
|
Fresenius Medical Care
|
||||||||
Quarterly Performance Scorecard - Dialysis Care Volume
|
||||||||
Three months ended September 30,
|
2011
|
2010
|
||||||
unaudited
|
||||||||
North America
|
||||||||
Number of treatments
|
5,489,224 | 5,281,436 | ||||||
Treatments per day
|
69,484 | 66,854 | ||||||
Per day sequential growth
|
0.7 | % | 0.5 | % | ||||
Per day year-over-year growth
|
3.9 | % | 4.4 | % | ||||
Same market growth year-over-year
|
2.9 | % | 4.3 | % | ||||
International
|
||||||||
Number of treatments
|
3,407,680 | 2,868,115 | ||||||
Same market growth year-over-year
|
6.5 | % | 5.6 | % |
Fresenius Medical Care
|
||||||||
Quarterly Performance Scorecard - Expenses
|
||||||||
Three months ended September 30,
|
2011
|
2010
|
||||||
unaudited
|
||||||||
North America
|
||||||||
Costs of revenue and operating expenses and income from equity method investees
|
||||||||
In percent of revenue
|
81.7 | % | 81.9 | % | ||||
Selling, general and administrative
|
||||||||
In percent of revenue
|
18.2 | % | 16.8 | % | ||||
Bad debt expenses
|
||||||||
In percent of revenue
|
2.9 | % | 2.2 | % | ||||
U.S. Dialysis Care operating expenses/treatment (in $)
|
279 | 289 | ||||||
Sequential growth
|
(1.3 | )% | (1.0 | )% | ||||
Growth year-over-year
|
(3.6 | )% | 0.7 | % | ||||
Dialysis Care operating expenses/treatment (in $)
|
274 | 284 | ||||||
Sequential growth
|
(1.1 | )% | (1.1 | )% | ||||
Growth year-over-year
|
(3.5 | )% | 0.4 | % | ||||
Total Group
|
||||||||
Costs of revenue and operating expenses and income from equity method investees
|
||||||||
In percent of revenue
|
83.5 | % | 83.9 | % | ||||
Selling, general and administrative
|
||||||||
In percent of revenue
|
18.5 | % | 17.7 | % | ||||
Effective tax rate
|
35.0 | % | 36.2 | % |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
16 of 18
|
Fresenius Medical Care
|
||||||||
Quarterly Performance Scorecard - Cash Flow/Investing Activities
|
||||||||
Three months ended September 30,
|
2011
|
2010
|
||||||
(in $ thousands, except number of de novos)
|
||||||||
unaudited
|
||||||||
Total Group
|
||||||||
Operating cash flow
|
463,137 | 383,671 | ||||||
In percent of revenue
|
14.3 | % | 12.5 | % | ||||
Free cash flow before acquisitions
|
313,323 | 262,258 | ||||||
In percent of revenue
|
9.7 | % | 8.6 | % | ||||
Acquisitions and Investments, net of divestitures
|
48,835 | 86,174 | ||||||
Capital expenditures, net
|
149,814 | 121,413 | ||||||
In percent of revenue
|
4.6 | % | 4.0 | % | ||||
Maintenance
|
84,480 | 69,987 | ||||||
In percent of revenue
|
2.6 | % | 2.3 | % | ||||
Growth
|
65,334 | 51,426 | ||||||
In percent of revenue
|
2.0 | % | 1.7 | % | ||||
Number of de novos
|
25 | 28 | ||||||
North America
|
9 | 15 | ||||||
International
|
16 | 13 |
Fresenius Medical Care
|
||||||||
Quarterly Performance Scorecard - Balance Sheet
|
||||||||
September 30,
|
2011
|
2010
|
||||||
unaudited
|
||||||||
Total Group
|
||||||||
Debt (in $ million)
|
6,711 | 5,736 | ||||||
Debt/EBITDA
|
2.6 | 2.4 | ||||||
North America
|
||||||||
Days sales outstanding
|
55 | 53 | ||||||
International
|
||||||||
Days sales outstanding
|
118 | 114 |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
17 of 18
|
Fresenius Medical Care
|
||||||||
Quarterly Performance Scorecard
|
||||||||
Three months ended September 30,
|
2011
|
2010
|
||||||
North America (U.S.)
|
||||||||
Clinical Performance
|
||||||||
Single Pool Kt/v > 1.2
|
97 | % | 96 | % | ||||
Hemoglobin = 10-12g/dl
|
77 | % | 69 | % | ||||
Hemoglobin = 10-13g/dl
|
89 | % | 88 | % | ||||
Calcium = 8.4-10.2mg/dl
|
80 | % | 80 | % | ||||
Albumin >= 3.5 g/dl 1)
|
84 | % | 82 | % | ||||
No catheter
|
78 | % | 75 | % | ||||
Phosphate <= 5.5mg/dl
|
64 | % | 63 | % | ||||
Hospitalization days per patient (12 months ending September 30)
|
9.8 | 9.8 | ||||||
Demographics
|
||||||||
Average age (in years)
|
62 | 62 | ||||||
Average time on dialysis (in years)
|
3.8 | 3.7 | ||||||
Average body weight (in kg)
|
81 | 81 | ||||||
Prevalence of diabetes
|
56 | % | 55 | % |
Fresenius Medical Care
|
||||||||
Quarterly Performance Scorecard
|
||||||||
Three months ended September 30,
|
2011
|
2010
|
||||||
Europe, Middle East and Africa
|
||||||||
Clinical Performance
|
||||||||
Single Pool Kt/v > 1.2
|
96 | % | 95 | % | ||||
Hemoglobin = 10-12g/dl
|
56 | % | 54 | % | ||||
Hemoglobin = 10-13g/dl
|
79 | % | 77 | % | ||||
Calcium = 8.4-10.2mg/dl
|
79 | % | 79 | % | ||||
Albumin >= 3.5 g/dl 1)
|
87 | % | 88 | % | ||||
No catheter
|
81 | % | 82 | % | ||||
Phosphate <= 5.5mg/dl
|
76 | % | 77 | % | ||||
Hospitalization days per patient (12 months ending September 30)
|
9.2 | 9.4 | ||||||
Demographics
|
||||||||
Average age (in years)
|
64 | 64 | ||||||
Average time on dialysis (in years)
|
4.9 | 4.8 | ||||||
Average body weight (in kg)
|
71 | 70 | ||||||
Prevalence of diabetes
|
28 | % | 27 | % |
Fresenius Medical Care AG & Co. KGaA, November 2, 2011
|
18 of 18
|